PHAR
Pharming Group NVNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.20B
P/E Ratio
424.50
EPS
$0.04
Beta
0.12
52W High
$21.34
52W Low
$7.79
50-Day MA
$16.63
200-Day MA
$14.86
Dividend Yield
—
Profit Margin
0.76%
Forward P/E
100.00
PEG Ratio
—
About Pharming Group NV
Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Leiden, the Netherlands.
Fundamentals
| Revenue (TTM) | $376.13M |
| Gross Profit (TTM) | $330.63M |
| EBITDA | $39.62M |
| Operating Margin | 2.84% |
| Return on Equity | 1.02% |
| Return on Assets | 4.55% |
| Revenue/Share (TTM) | $5.46 |
| Book Value | $0.42 |
| Price-to-Book | 4.21 |
| Price-to-Sales (TTM) | 3.19 |
| EV/Revenue | 2.929 |
| EV/EBITDA | 31.67 |
| Quarterly Earnings Growth (YoY) | 104.20% |
| Quarterly Revenue Growth (YoY) | 15.00% |
| Shares Outstanding | $70.63M |
| Float | $680.61M |
| % Insiders | 0.00% |
| % Institutions | 0.21% |
Analyst Ratings
Consensus ($33.80 target)
3
BuyData last updated: 4/9/2026